Literature DB >> 11854287

Phosphoinositide 3-kinase activity is required for retinoic acid-induced expression and activation of the tissue transglutaminase.

Marc A Antonyak1, Jason E Boehm, Richard A Cerione.   

Abstract

Tissue transglutaminase (TGase) is a dual function enzyme that couples an ability to bind GTP with transamidation activity. Retinoic acid (RA) consistently induces TGase expression and activation, and it was recently shown that increased TGase expression protected cells from apoptosis. To better understand how RA regulates TGase, we considered whether RA employed pro-survival signaling pathways to mediate TGase expression and activation. It was found that RA stimulation of NIH3T3 cells activated ERK and phosphoinositide 3-kinase (PI3K); however, only PI3K activation was necessary for RA-induced TGase expression. The overexpression of a constitutively active form of PI3K did not induce TGase expression, indicating that PI3K signaling was necessary but not sufficient for TGase expression. The exposure of cells expressing exogenous TGase to the PI3K inhibitor, LY294002, reduced the ability of TGase to be photoaffinity-labeled with [alpha-(32)P]GTP, providing evidence that PI3K regulates the GTP binding activity of TGase as well as its expression. Moreover, cell viability assays showed that incubation of RA-treated cells with LY294002 together with the TGase inhibitor, monodansylcadaverine (MDC), converted RA from a differentiation factor to an apoptotic stimulus. These findings demonstrate that PI3K activity is required for the RA-stimulated expression and GTP binding activity of TGase, thereby linking the up-regulation of TGase with a well established cell survival factor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854287     DOI: 10.1074/jbc.M112259200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

2.  Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells.

Authors:  Hirohito Yamaguchi; Hong-Gang Wang
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

3.  Krüppel-like factor 4 inhibits proliferation by platelet-derived growth factor receptor beta-mediated, not by retinoic acid receptor alpha-mediated, phosphatidylinositol 3-kinase and ERK signaling in vascular smooth muscle cells.

Authors:  Bin Zheng; Mei Han; Michel Bernier; Xin-hua Zhang; Fang Meng; Sui-bing Miao; Ming He; Xin-ming Zhao; Jin-kun Wen
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

4.  Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion.

Authors:  Marc A Antonyak; Bo Li; Andrew D Regan; Qiyu Feng; Stephanie S Dusaban; Richard A Cerione
Journal:  J Biol Chem       Date:  2009-04-29       Impact factor: 5.157

Review 5.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

Review 6.  Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.

Authors:  P G Mastroberardino; M Piacentini
Journal:  J Intern Med       Date:  2010-11       Impact factor: 8.989

7.  Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.

Authors:  Stephen J McConoughey; Manuela Basso; Zoya V Niatsetskaya; Sama F Sleiman; Natalia A Smirnova; Brett C Langley; Lata Mahishi; Arthur J L Cooper; Marc A Antonyak; Rick A Cerione; Bo Li; Anatoly Starkov; Rajnish Kumar Chaturvedi; M Flint Beal; Giovanni Coppola; Daniel H Geschwind; Hoon Ryu; Li Xia; Siiri E Iismaa; Judit Pallos; Ralf Pasternack; Martin Hils; Jing Fan; Lynn A Raymond; J Lawrence Marsh; Leslie M Thompson; Rajiv R Ratan
Journal:  EMBO Mol Med       Date:  2010-09       Impact factor: 12.137

8.  A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells.

Authors:  William P Katt; Nicolas J Blobel; Svetlana Komarova; Marc A Antonyak; Ichiro Nakano; Richard A Cerione
Journal:  Oncotarget       Date:  2018-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.